TMEM164 Inhibitors
TMEM164 Inhibitors are a class of chemicals that decrease the expression of TMEM164, a positive regulator of ferroptosis. These inhibitors work through a variety of mechanisms, some of which inhibit the same cellular processes that TMEM164 promotes. For example, Ferrostatin-1 and Liproxstatin-1 directly inhibit ferroptosis, thereby counteracting TMEM164's role in facilitating this form of cell death. Iron-chelating agents such as Desferrioxamine and Deferasirox specifically target TMEM164's function in increasing intracellular iron levels to promote ferroptosis. On the other hand, inhibitors like 3-Methyladenine and Chloroquine target autophagosome formation and fusion, which are selective actions of TMEM164 during ferroptosis.
Other inhibitors such as LY294002 and Wortmannin target the PI3K/Akt signaling pathway, affecting autophagy and, consequently, the role of TMEM164 in ATG5-dependent autophagosome formation. PD98059 operates by inhibiting the MAPK/ERK pathway, which could also impact TMEM164's regulation of ferritin degradation. By inhibiting these signaling pathways, the compounds effectively suppress TMEM164's ability to carry out its functions, offering multiple points of intervention. These inhibitors thereby provide a comprehensive approach to modulating TMEM164's diverse roles in ferroptosis and autophagy.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Ferrostatin 1 | 347174-05-4 | sc-498126 sc-498126A | 10 mg 50 mg | $165.00 $451.00 | 15 | |
Ferrostatin 1 inhibits ferroptosis, and thereby counteracts TMEM164's role in promoting ferroptotic cell death. | ||||||
Zileuton | 111406-87-2 | sc-204417 sc-204417A sc-204417B sc-204417C | 10 mg 50 mg 1 g 75 g | $84.00 $307.00 $369.00 $1254.00 | 8 | |
Zileuton inhibits 5-lipoxygenase, reducing lipid peroxidation, which counteracts TMEM164's role in promoting ferroptosis. | ||||||
Deferoxamine | 70-51-9 | sc-507390 | 5 mg | $255.00 | ||
Desferrioxamine chelates iron, reducing iron accumulation, thereby inhibiting the effect of TMEM164 on iron accumulation. | ||||||
Deferasirox | 201530-41-8 | sc-207509 | 2.5 mg | $180.00 | 9 | |
Deferasirox also chelates iron and reduces iron accumulation, inhibiting TMEM164's function in increasing iron levels for ferroptosis. | ||||||
N-Acetyl-L-cysteine | 616-91-1 | sc-202232 sc-202232A sc-202232C sc-202232B | 5 g 25 g 1 kg 100 g | $34.00 $74.00 $270.00 $114.00 | 34 | |
N-Acetyl-L-cysteine acts as an antioxidant, neutralizing the effects of lipid peroxidation, counteracting TMEM164's role in ferroptosis. | ||||||
Baicalein | 491-67-8 | sc-200494 sc-200494A sc-200494B sc-200494C | 10 mg 100 mg 500 mg 1 g | $32.00 $42.00 $162.00 $292.00 | 12 | |
Baicalein inhibits lipoxygenases, reducing lipid peroxidation, and thereby counteracting TMEM164's role in promoting ferroptosis. | ||||||
Autophagy Inhibitor, 3-MA | 5142-23-4 | sc-205596 sc-205596A | 50 mg 500 mg | $65.00 $261.00 | 113 | |
Autophagy Inhibitor, 3-MA inhibits autophagosome formation, which can inhibit TMEM164's function in selectively mediating ATG5-dependent autophagosome formation during ferroptosis. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $69.00 | 2 | |
Chloroquine blocks autophagosome-lysosome fusion, thus inhibiting the downstream effects of TMEM164 in ferroptosis through autophagy. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 inhibits PI3K, which is upstream of autophagy and could therefore inhibit TMEM164's role in ATG5-dependent autophagosome formation. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 inhibits the MAPK/ERK pathway, which could interfere with TMEM164's regulation of ferritin degradation and thus its promotion of ferroptosis. | ||||||